269 related articles for article (PubMed ID: 21738117)
1. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.
Langsteger W; Balogova S; Huchet V; Beheshti M; Paycha F; Egrot C; Janetschek G; Loidl W; Nataf V; Kerrou K; Pascal O; Cussenot O; Talbot JN
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):448-57. PubMed ID: 21738117
[TBL] [Abstract][Full Text] [Related]
2. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
3. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
4. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Loidl W; Broinger G; Stoiber F; Foglman I; Langsteger W
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1766-74. PubMed ID: 18465129
[TBL] [Abstract][Full Text] [Related]
5. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
BJU Int; 2012 Nov; 110(10):1501-6. PubMed ID: 22502982
[TBL] [Abstract][Full Text] [Related]
6. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
[TBL] [Abstract][Full Text] [Related]
7. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
[TBL] [Abstract][Full Text] [Related]
8. Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose.
Balogova S; Huchet V; Kerrou K; Nataf V; Gutman F; Antoine M; Ruppert AM; Prignon A; Lavolée A; Montravers F; Mayaud C; Cadranel J; Talbot JN
Nucl Med Commun; 2010 May; 31(5):389-97. PubMed ID: 20145579
[TBL] [Abstract][Full Text] [Related]
9. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
[TBL] [Abstract][Full Text] [Related]
10. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
11. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2009; 11(6):446-54. PubMed ID: 19326171
[TBL] [Abstract][Full Text] [Related]
12. Comparison of
Gauthé M; Zarca K; Aveline C; Lecouvet F; Balogova S; Cussenot O; Talbot JN; Durand-Zaleski I
BMC Med Imaging; 2020 Mar; 20(1):25. PubMed ID: 32122345
[TBL] [Abstract][Full Text] [Related]
13. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.
Wondergem M; van der Zant FM; van der Ploeg T; Knol RJ
Nucl Med Commun; 2013 Oct; 34(10):935-45. PubMed ID: 23903557
[TBL] [Abstract][Full Text] [Related]
14. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
15. Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer.
Beauregard JM; Williams SG; Degrado TR; Roselt P; Hicks RJ
J Med Imaging Radiat Oncol; 2010 Aug; 54(4):325-32. PubMed ID: 20718912
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.
Beheshti M; Rezaee A; Geinitz H; Loidl W; Pirich C; Langsteger W
J Nucl Med; 2016 Oct; 57(Suppl 3):55S-60S. PubMed ID: 27694173
[No Abstract] [Full Text] [Related]
17. 18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.
Gillebert Q; Huchet V; Rousseau C; Cochet A; Olivier P; Courbon F; Gontier E; Nataf V; Balogova S; Talbot JN;
PLoS One; 2018; 13(2):e0191487. PubMed ID: 29425221
[TBL] [Abstract][Full Text] [Related]
18. Impact of sodium
Gauthé M; Aveline C; Lecouvet F; Michaud L; Rousseau C; Tassart M; Cussenot O; Talbot JN; Durand-Zaleski I
World J Urol; 2019 Aug; 37(8):1587-1595. PubMed ID: 30382380
[TBL] [Abstract][Full Text] [Related]
19. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2010; 12(1):98-107. PubMed ID: 19588206
[TBL] [Abstract][Full Text] [Related]
20. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN
Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
